Compare Nvidia Corp (NVDA) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nvidia Corp vs Novo Nordisk A/S — how do they compare? Nvidia Corp trades at $206.49 (market cap $4.92T), while Novo Nordisk A/S trades at $49.36 (market cap $220.53B). The key difference: Nvidia Corp is far larger — about 22.3× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVDA | NVO | |
|---|---|---|
Market Cap | $4.92T | $220.53B |
Sector | Technology | Health |
52-Week High | $235.75 | $71.70 |
52-Week Low | $165.17 | $35.29 |
Enterprise Value | $4.86T | $239.49B |
Dividend Yield | 0.49% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVIDIA (NVDA) trades at $207.14, up 2.14% today, with a neutral technical signal and strong fundamentals. Recent earnings beats and robust profitability margins highlight operational strength. The stock is supported by a consensus analyst price target of $325.86, though it faces technical resistance near $210.
Outlook remains positive driven by AI chip demand, but risks include competition and market volatility. Revenue growth acceleration and high institutional ownership suggest long-term potential, yet valuation multiples require sustained execution to justify further upside.
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
